Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475.
Richard W. Joseph(Daiichi Sankyo (United States)), Tara C. Gangadhar(University of Pennsylvania), Andrea Perrone(Università Cattolica del Sacro Cuore), Jeroen Elassaiss‐Schaap(Merck & Co., Inc., Rahway, NJ, USA (United States)), Omid Hamid(Cedars-Sinai Medical Center), Jeffrey S. Weber(NYU Langone Health), Jedd D. Wolchok(Cornell University), Peter Hersey(The University of Sydney), Richard Kefford(Broad Institute), Amita Patnaik(South Texas Accelerated Research Therapeutics), Dinesh P. de Alwis(Merck & Co., Inc., Rahway, NJ, USA (United States)), Keaven M. Anderson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Antoni Ribas(University of California, Los Angeles), F. Stephen Hodi(Harvard University), Anthony M. Joshua(St Vincent's Hospital Sydney), Caroline Robert(Institut Gustave Roussy), Wen‐Jen Hwu(The University of Texas MD Anderson Cancer Center), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Soonmo Peter Kang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Adil Daud(University of California, San Francisco)
Cited by 35
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k